Literature DB >> 20458052

Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date?

Tim Martin Illidge1.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20458052     DOI： 10.1200/JCO.2009.26.8748

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  13 in total

1.  Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma.

Authors:  Franz Buchegger; Oliver W Press
Journal:  EJNMMI Res       Date:  2011-06-20       Impact factor: 3.138

2.  Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists.

Authors:  Niklaus G Schaefer; Peng Huang; Julia W Buchanan; Richard L Wahl
Journal:  J Nucl Med       Date:  2011-05       Impact factor: 10.057

3.  Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma.

Authors:  Qiushi Chen; Turgay Ayer; Loretta J Nastoupil; Adam C Rose; Christopher R Flowers
Journal:  Value Health       Date:  2015-03       Impact factor: 5.725

Review 4.  Unmet needs in the first-line treatment of follicular lymphoma.

Authors:  C Casulo; L Nastoupil; N H Fowler; J W Friedberg; C R Flowers
Journal:  Ann Oncol       Date:  2017-09-01       Impact factor: 32.976

5.  Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network.

Authors:  Karin Hohloch; H K Lankeit; P L Zinzani; C W Scholz; M Lorsbach; C Windemuth-Kieselbach; L Trümper
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-11       Impact factor: 9.236

Review 6.  Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma.

Authors:  Antonio C Sánchez Ruiz; Luis de la Cruz-Merino; Mariano Provencio Pulla
Journal:  Ther Adv Hematol       Date:  2014-06

7.  Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT.

Authors:  Thomas Carlier; Thomas Eugène; Caroline Bodet-Milin; Etienne Garin; Catherine Ansquer; Caroline Rousseau; Ludovic Ferrer; Jacques Barbet; Frédéric Schoenahl; Françoise Kraeber-Bodéré
Journal:  EJNMMI Res       Date:  2013-02-17       Impact factor: 3.138

8.  RIT with Y90-Ibritumomab Tiuxetan in Follicular Non-Hodgkin Lymphoma: Evaluation of Recent Outcomes in a Single Institution.

Authors:  Marcio Miguel Andrade Campos; Anel E Montes Limón; Jose María Grasa; Paola Lievano; Teresa Baringo; Pilar Giraldo
Journal:  J Oncol       Date:  2012-09-25       Impact factor: 4.375

9.  Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival.

Authors:  Julia Y Wagner; Kathleen Schwarz; Susanne Schreiber; Burkhard Schmidt; Hans-Jürgen Wester; Markus Schwaiger; Christian Peschel; Christoph von Schilling; Klemens Scheidhauer; Ulrich Keller
Journal:  Oncotarget       Date:  2013-06

10.  Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma.

Authors:  Caroline Bodet-Milin; Ludovic Ferrer; Amandine Pallardy; Thomas Eugène; Aurore Rauscher; Jacques Barbet; Françoise Kraeber-Bodéré
Journal:  Front Oncol       Date:  2013-07-11       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.